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Abstract 25 
 26 
Purpose: There is an increased interest in the benefits of conjugated α-linolenic acid (CLNA) on obesity-related 27 
complications such as insulin resistance and diabetes. The aim of the study was to investigate whether a 1% dietary 28 
supplementation of mono-CLNA isomers (c9-t11-c15-18:3 + c9-t13-c15-18:3) improved glucose and lipid metabolism in 29 
neonatal pigs. Methods: Since mono-CLNA isomers combine one conjugated two-double bond  system with an n-3 30 
polyunsaturated fatty acid (PUFA) structure, the experimental protocol was designed to isolate the dietary structural 31 
characteristics of the molecules by comparing a CLNA diet with three other dietary fats: 1) conjugated linoleic acid (c9-t11-32 
18:2 + t10-c12-18:2; CLA), 2) non-conjugated n-3 PUFA and 3) n-6 PUFA.  Thirty-two piglets weaned at 3 weeks of age 33 
were distributed into the four dietary groups. Diets were isoenergetic and food intake was controlled by a gastric tube. After 34 
2 weeks of supplementation, gastro-enteral (OGTT) and parenteral (IVGTT) glucose tolerance tests were conducted. 35 
Results: Dietary supplementation with mono-CLNA did not modify body weight/fat or blood lipid profiles (p>0.82 and 36 
p>0.57, respectively) compared with other dietary groups. Plasma glucose, insulin and C-peptide responses to OGTT and 37 
IVGTT in the CLNA group was not different from the three other dietary groups (p>0.18 and p>0.15, respectively). 38 
Compared to the non-conjugated n-3 PUFA diet, CLNA-fed animals had decreased liver composition in three n-3 fatty 39 
acids (18:3n-3; 20:3n-3; 22:5n-3) (p<0.001). Conclusions: These results suggest that providing 1% mono-CLNA is not 40 
effective in improving insulin sensitivity in neonatal pigs. 41 
 42 
Key words: conjugated linolenic acid: n-3 fatty acid: insulin resistance: pig  43 
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Introduction 44 
 45 
Conjugated fatty acids refer to a set of positional and geometric isomers of polyunsaturated fatty acids (PUFA) with 46 
conjugated double bonds. Conjugated linoleic acids (CLA) were first identified in the late eighties by Pariza et al. [1]. Since 47 
then, consumption of CLA was associated to weight loss [2] and improving of insulin sensitivity [3]. Another group of 48 
conjugated fatty acids recently received more attention because it combined an n-3 and a conjugated double bond: 49 
conjugated α-linolenic acids (CLNA) [4]. CLNA isomers are naturally present in plant seeds (di-CLNA) and in dairy 50 
products (mono-CLNA). Mono- and di-CLNA differ by their conjugated double-bond system: mono-CLNA have a single 51 
conjugated double-bond system at the n-5 or n-7 carbon, i.e rumelenic acid, c9-t11-c15-18:3, whereas di-CLNA have a 52 
double conjugated double-bond system at the n-5/n-7 or n-8/n-10 carbons, i.e α-eleostaric acid c9-t11-t13-18:3. Mono-53 
CLNA isomers are produced by biohydrogenation of α-linolenic acid by rumen bacteria [5, 6].  54 
Because of the worldwide problem of obesity in children and the related health problems such as hypertension and diabetes 55 
mellitus [7], there is an increased interest in the development of preventive and therapeutic strategies for improving insulin 56 
resistance  [8]. Indeed, using antidiabetic drugs is not appropriate for treating diabetes in children unless there is severe 57 
glucose intolerance, thereby finding natural strategies such as CLNA isomers is an attractive approach which deserves to be 58 
studied. Di-CLNA are able to decrease body weight [9] and fat[10, 11], as well as increase insulin sensitivity in rodents [9, 59 
12, 13]. Some studies also reported that either CLA [14] or n-3 PUFA [15] or the combination of the two [16] could 60 
improve glucose tolerance. Since a mono-CLNA such as c9-t11-c15-18:3 isomer combines the conjugated double bond 61 
system of CLA and the n-3 double bond of α-linolenic acid, it is reasonable to speculate that this original fatty acid structure 62 
may provide similar or even enhanced glucose tolerance than the conjugated or n-3 double bond structure. 63 
Bioavailability of mono-CLNA was reported to be high in rodents. The metabolism of mono-CLNA has already been 64 
studied in different animal models excluding pigs [5, 6, 17].   65 
The objective of the present study was to investigate whether dietary supplementation with mono-CLNA (c9-t11-c15-18:3 + 66 
c9-t13-c15-18:3) improves glucose metabolism in neonatal piglets. In order to isolate the role of the conjugated double-67 
bond in combination with the n-3 PUFA structure, mono-CLNA group will be compared with three other dietary treatments: 68 
CLA isomers, non-conjugated n-3 and non-conjugated n-6 PUFAs. 69 
 70 
Methods and materials 71 
 72 
Animals and diets 73 
Thirty two Yorkshire × Landrace × Duroc piglets (females and castrated males) weaned at 3 weeks of age were separated 74 
into eight groups of four animals. To control for food intake, an oesophageal gastric tube was installed into all animals as 75 
previously described by Cortamira et al. [18]. Individual adjoining metabolism cages with plastic floors allowed free 76 
movement and room temperature was kept at 27°C. At baseline, average body weight was 7.6 ± 0.4 kg. Within each group 77 
the piglets (from the same litter) were assigned to one of four dietary treatment groups, fed entirely with a commercial diet 78 
(barley (25%), maize (20%), dried whey (20%), soybean meal (10%), extruded soybean (8%) and plasma protein (5%); 79 
Table 1) plus either 1% of the caloric intake of the basal diet in the form of one the following lipid emulsion of specific fatty 80 
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acids: (1) synthetic mixture of two mono-conjugated α-linolenic acids (c9-t11-c15-18:3 + c9-t13-c15-18:3; CLNA); (2) 81 
mixture of two conjugated linoleic acids (c9-t11-18:2 + t10-c12-18:2; CLA); (3) n-3 fatty acids (W3); or (4) n-6 fatty acids 82 
(W6).  83 
Mono-CLNA isomers were synthesized by alkali isomerization of α-linolenic acid. Thereafter, CLNA isomers were purified 84 
by preparative chromatography using a reverse phase column,  as previously described by Trottier [19]. The fatty acid 85 
profile of the four lipid emulsions is shown in Table 2.  86 
All diets were isoenergetic. The feeding regime was based on daily increment of 7.1 g feed per kg
0.75 
body weight (g/kg
0.75
) 87 
up to the target maximum daily value of 56 g/kg
0.75
. The daily intake was adjusted three times per week according to 88 
changes in body weight in order to maintain the weight stable.
 
Basal diet was mixed with water (1:2) and infused with a 89 
syringe into the stomach via the gastric tube. Daily meals were given at 08:00, 11:30 and 16:00 hours; each representing 90 
45%, 20% and 35% of the diet caloric intake, respectively. Dietary treatments were given during the morning meal. Before 91 
the morning meal on day 0 (before attribution of treatments) and on day 15 post-weaning, body weight was measured and 92 
blood samples were collected via jugular venipuncture as previously described by Matte et al. [20]. 93 
On day 9 of the experimental protocol, a jugular catheter was installed by a non-surgical technique described by Matte et al. 94 
[21]. All animals were tested for insulin resistance by two glucose tolerance tests: a gastro-enteral (OGTT) and a parenteral 95 
(IVGTT) test. Briefly, after fasting for 18h, piglets (n=32) were given either an oral (OGTT) or an IV (IVGTT) dose of 96 
glucose (1.0g/kg BW) over a period of 120 min. Blood samples were collected every 30 min for 240 min (0, 30, 60, 90, 120, 97 
150, 180, 210 and 240 min) starting after the initial glucose infusion. Blood samples were centrifuged at 3000 rpm for 10 98 
min at 4°C and plasma was stored at -20°C until glucose, insulin and C-peptide analyses were performed. Two days after 99 
the first glucose test, the protocol was repeated with the other glucose test using the same animal. All animals were 100 
sacrificed on day 17. The liver was removed, weighed and samples were stored at -20°C for further analysis. The digestive 101 
tract, brain, lungs and heart were removed and stored at –20°C until lipid quantification was performed. 102 
Throughout the experimental protocol animals were cared for according to the recommended code of practice of Agriculture 103 
Canada [22] and the procedure was approved by the local Animal Care Committee following the guidelines of the Canadian 104 
Council on Animal Care [23]. 105 
 106 
Biochemical analyses 107 
Plasma glucose was measured by an enzymatic colorimetric assay (GLU GOD-PAP; Roche Diagnostics, Indianapolis, IN, 108 
USA) whereas insulin (Porcine Insulin RIA Kit PI-12K; Linco Research Inc., St Charles, MI USA) and C-peptide (Porcine 109 
C-peptide RIA kit PCP-22k; Linco Research Inc.) were assayed by commercial RIA kits.  The homeostatic model 110 
assessment (HOMA2), described by Levy et al. [24] was used to estimate insulin sensitivity (HOMA2-%S) and secretion 111 
(HOMA2-%B) from baseline plasma parameters measured during OGTT and IVGTT. The area under the curve (AUC) of 112 
glucose, insulin and C-peptide were calculated using the trapezoidal method [25] between 0 and 210 min. Matsuda’s insulin 113 
sensitivity whole-body index (ISI) was also calculated from the data generated during the OGTT [26]. An insulin sensitivity 114 
index (SI) derived from the IVGTT was calculated according to a modified method described by Bergman and colleagues 115 
[27, 28]. 116 
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SI was determined from 120 to 210 min of the IVGTT, i.e. after the end of the infusion to assess the deconvolution of 117 
glucose with regards to insulin after the glucose peak. Total cholesterol, triglyceride and non-esterified fatty acid (NEFA) 118 
concentration in plasma at day 1 and day 15 were measured by the service diagnostic of the Faculty of Veterinary Medicine 119 
at the Université de Montréal (Montreal, QC, Canada). The fatty acid composition of the four diets and liver was 120 
determined by gas chromatography as previously described by Castellano et al. [29]. 121 
 122 
Statistical Analysis 123 
According to results obtained from similar porcine studies [15], the calculated sample size per group (n = 8) was sufficient 124 
to detect a difference in insulin sensitivity of at least 15% with a power of 80% and a level of significance of 0.05. 125 
The data were analyzed by using the MIXED procedure implemented in Statistical Analysis Systems software (version 6.11 126 
of SAS, Cary, NC, USA) [30] according to a completely randomised design with four treatments (CLNA, CLA, W3, and 127 
W6) as the main factor. The piglet was considered as the experimental unit. The following model was used:  128 
Yij = µ + Fi + eij 129 
where Yij is the dependent variable, µ is the overall mean, Fi is the treatment effect and eij is the residual error. Comparisons 130 
among treatments were done using the following a priori contrasts (CLNA vs. W3 for CLA properties; CLNA vs. W6 for 131 
both CLA and n-3 PUFA properties; CLNA vs. CLA for n-3 PUFA properties) using a Dunnett’s correction. All values are 132 
presented as mean ± SEM and differences are considered significant at p<0.05. 133 
 134 
Results 135 
 136 
Anthropometry and blood lipid parameters 137 
Body weight of piglets pre-treatment was 7.6 ± 0.4 kg. After 2 weeks of supplementation (day 15), there was no difference 138 
(p>0.82) between treatments for either body weight (10.2 ± 0.4 kg) or fat content (10.0 ± 0.8 %). Total cholesterol, 139 
triglyceride and NEFA concentrations in blood plasma for day 1 vs. day 15 were, 5.9 ± 0.8 vs. 2.0 ± 0.1 mmol/l, 0.7 ± 0.1 140 
vs. 0.3 ± 0.1 mmol/l and 708.3 ± 146.7 vs. 769.6 ± 101.8 μmol/l, respectively. There was no difference (p>0.34) according 141 
to dietary treatments for these parameters. 142 
 143 
Liver fatty acid profile 144 
There was no significant difference (p=0.67) in liver weight between dietary treatments.  The overall organ weight was 248 145 
± 14 g. Evaluation of liver fatty acid composition was used as an indicator of whole body fatty acid status modification from 146 
dietary treatments. Mono-CLNA (c9-t11-c15-18:3 + c9-t13-c15-18:3) liver content, was higher (p<0.001) in the CLNA diet 147 
than the other diets (0.25 vs. 0.01 g/100g fatty acids, respectively). With regards to n-3 fatty acids, 18:3n-3, 20:3n-3 and 148 
22:5n-3 were 20 to 40% lower (p<0.001) in CLNA diets compared to the W3 diet. Total n-3 PUFA was also significantly 149 
lower (p<0.001) in the CLNA diet than the W3 diet (9.27 vs. 10.77 g/100g fatty acids, respectively). In contrast, the 150 
proportion of arachidonic acid (20:4n-6) was 8% higher in the CLNA group compared to the W3 group, resulting in a 151 
significantly higher total n-6 PUFA level (CLNA vs. W3, 40.61 vs. 39.52 g/100g fatty acids, respectively). 152 
 153 
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Basal plasma glucose, insulin and C-peptide concentration 154 
Baseline plasma glucose, insulin and C-peptide concentrations were evaluated before the OGTT or IVGTT load of glucose 155 
(Table 3). A significant treatment effect was detected for fasting insulin concentration on the OGTT day (p=0.03) and on 156 
calculated insulin sensitivity HOMA-%S but the specific contrast test did not allow discrimination between the CLNA 157 
group and the other dietary groups (p>0.22). There was no other treatment difference for OGTT and IVGTT (p>0.14; Table 158 
3).   159 
 160 
Monitoring of glucose, insulin and C-peptide during OGTT and IVGTT 161 
AUC for glucose, insulin and C-peptide monitored between 0 and 210 min are reported in Table 4. Among the four dietary 162 
groups, there was no significant difference in glucose, insulin and C-peptide monitoring over the OGTT and the IVGTT. 163 
Dietary intake did not improve the Matsuda’s ISI (p=0.71) calculated from the OGTT nor the minimal model-derived 164 
insulin sensitivity calculated from the IVGTT (SI; p=0.51).  165 
 166 
Discussion 167 
 168 
The present study aimed to investigate whether dietary supplementation with mono-CLNA improves body composition and 169 
glucose tolerance in neonatal piglets. 170 
This model was chosen because piglets represent 1) an accelerated model of postnatal development to study human neonatal 171 
nutrition and development [31], 2) a relevant model for insulin resistance [32] and 3) a suitable model for evaluating 172 
nutritional strategies to enhance glucose tolerance and prevent type 2 diabetes and cardiovascular diseases later in life [33].  173 
 174 
Body composition and blood lipids 175 
Mono-CLNA might combine anti-obesity properties of CLA, along with those of the α-linolenic acid. There is evidence 176 
suggesting that CLA decreases body weight, fat accumulation and improves serum lipids in mice [34], rats [35], hamsters 177 
[36] and humans [37]. Similarly, α-linolenic acid was reported to improve the same biomarkers in hamsters [38] and 178 
humans [39]. Many studies in rodents [10-12, 40-42]  showed that dietary di-CLNA supplementation decreases body 179 
weight, body fat as well as plasma triglycerides and cholesterol. This study speculates that because mono-CLNA has an 180 
original structure compared to di-CLNA, this conjugated fatty acid will have improved or equally effective glucose 181 
tolerance than CLA or α-linolenic acid alone. None of them combined an n-3 PUFA and a CLA structure. However, dietary 182 
supplementation of piglets with mono-CLNA for 14 days did not improve body weight, body fat nor blood lipid profiles. 183 
Our findings extend previous studies in rodents which reported that dietary mono-CLNA did not lower body weight [17, 184 
43]. By analogy, dietary di-CLNA isomers did not lower adipose tissue weight as well as total cholesterol and triglycerides 185 
in the plasma of animals [12, 17, 42, 44, 45] and humans [46].  186 
 187 
Liver fatty acid composition 188 
CLNA and CLA concentrations in liver reflected the dietary intake of these fatty acids. This response suggests that a 2-189 
week supplementation was sufficient for stabilization of PUFA status within the piglet’s body. Our results are in the line 190 
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with Chartrand et al. [47] who reported that dietary fatty acid content consumed for at least 14 days was proportional to 191 
plasma fatty acid profiles and remained constant up to study completion at 36 days. Our results also showed that giving 192 
mono-CLNA to piglets changed the n-3 and n-6 fatty acid balance. More specifically, compared to the W3 diet, feeding 193 
mono-CLNA for 2 weeks decreased the proportions of 18:3n-3, 20:3n-3, 20:5n-3, 22:5n-3 together with an increase in 194 
20:4n-6 and total n-6 PUFA content. Since a previous study in mice reported that n-3 PUFA chronic depletion in the liver 195 
led to the development of hepatic insulin resistance over a 3 month period [48],  further studies need to be carried out for  an 196 
extended period of time in pigs fed CLNA with additional health indicators (blood biochemical, other tissue lipid profile, 197 
etc) in order to better assess the safety aspects of consuming dietary mono-CLNA isomers. 198 
 199 
Glucose tolerance 200 
One of our hypotheses was that combining a conjugated and an n-3 PUFA structure in one fatty acid, like mono-CLNA, 201 
would improve insulin sensitivity considering that dietary CLA seems to lower insulinemia in rats [49] and α-linolenic acid 202 
intake seems to reduce insulin resistance in rats [50] and in humans [51].  203 
Our results suggest a significant treatment effect for fasting insulin concentration and insulin sensitivity on the OGTT day 204 
(p=0.03). However, we consider that this result is unlikely of biological significance because specific a priori contrasts 205 
indicate that there is no treatment effect of mono-CLNA diet compared to the three other dietary groups. Moreover, these 206 
differences were not confirmed at the day of IVGTT or during the two glucose tolerance tests. One possible explanation 207 
could be a higher insulin secretion generated by environmental/psychological stresses during the first experiment, i.e. 208 
human presence, handling, noise, etc [52, 53]. Also, no treatment effect was seen on C-peptide, a good indicator of 209 
endogenous insulin secretion [54], either for OGTT or IVGTT. 210 
In regards to the different indexes of insulin sensitivity (HOMA2-%S, ISIMatsuda and SI) and insulin secretion (Insulin and C-211 
peptide levels, AUCs and HOMA2-%B), none were improved by ingestion of mono-CLNA for 2 weeks. 212 
Results on a closer structural analog to mono-CLNA such as di-CLNA showed some inconsistency. Indeed, although 213 
several studies reported that dietary supplementation with di-CLNA isomers can decrease type 2 diabetes risk [12] and 214 
improve glucose tolerance [9, 55] in mice, others reported an increase in insulin resistance (HOMA-IR index) in rats [44] 215 
similar to what is reported in mice [56, 57], pigs [58], and humans [59]. Moreover, most of the studies using n-3 PUFA 216 
supplement in humans failed to improve insulin sensitivity [60, 61]. 217 
 218 
Limitations of the present study 219 
The present study extends previous findings [9, 40, 44, 55] using a neonatal pig model and randomised experimental design 220 
to compare mono-CLNA diet vs. three other dietary treatments (CLA, W3, and W6). Nevertheless, it has some limitations 221 
including the duration of the supplementation and the composition of the CLA diet, since we used a mixture of two isomers: 222 
c9-t11-18:3 + t10-c12-18:3. Even if most previous studies have used a CLA isomer mixture, recent findings show that 223 
purified CLA isomers could have opposite actions on glucose tolerance, with t10-c12-18:3 reducing insulin sensitivity and 224 
c9-t11-18:3 enhancing insulin tolerance [3]. Mono-CLNA was also a mixture of two isomers and this is mostly because it is 225 
not possible to cost effectively separate the two CLNA isomers for generating high doses of single CLNA isomers for 226 
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feeding animals. Therefore, a direct comparison between CLA and CLNA diets based only on the chemical structure is 227 
limited. 228 
 229 
Conclusions 230 
This study showed that mono-CLNA, combining conjugated and an n-3 double-bound structure, did not provide additive 231 
improvement for body composition, glucose tolerance or blood lipid profile in the neonatal piglet model supplemented for a 232 
period of 2 weeks. Conversely, mono-CLNA decreased total n-3 PUFA in liver, a finding which merits consideration in 233 
regards to neonatal development and safety.  234 
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Table 1: Composition of basal diet 395 
Ingredients Calculated concentration 
Digestible energy (MJ/kg) 14.98 
Total protein (%) 19.94 
Crude fibre (%) 1.90 
Fat (%) 7.49 
Lysine (%) 1.40 
Methionine (%) 0.43 
Tryptophan (%) 0.24 
Calcium (%) 0.80 
Phosphorus (%) 0.70 
Provided (per kg basal diet): Mn, 40 mg; Zn, 2935 mg; Fe, 299 mg; Cu, 19 mg; I, 2 mg; Se 297 μg; vitamin 
A, 4.9 mg; vitamin D, 37.5 μg; vitamin E,  66.8 mg; menadione, ; thiamin, 2.7 mg; riboflavin, 8.7 mg; 
niacin, 31 mg; panthothenic acid 21.2 mg; folic acid, 0.7 mg; pyridoxine, 2.6 mg; biotin, 120 μg; vitamin 
B12, 25.1 μg; choline, 303 mg 
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Table 2: Analytical fatty acid composition (g/100 g fatty acids) of lipid emulsions added to the dietary treatments 397 
Fatty acid CLNA CLA W3 W6 
16:0 6.37 6.04 6.10 5.97 
16:1n-7 0.05 0.04 0.07 0.08 
18:0 3.23 3.39 3.60 3.63 
18:1n-9 22.40 21.61 23.39 22.89 
18:1n-7 0.01 0.04 0.06 0.05 
18:2n-6 15.72 19.49 18.58 53.08 
18:3n-3 12.65 13.24 46.99 12.88 
18:3n-6 0.19 0.08 0.21 0.10 
20:0 0.06 0.14 0.14 0.23 
20:1n-9 0.02 0.01 0.02 0.08 
20:2n-6 1.72 1.50 0.06 0.07 
20:3n-3 0.40 0.04 0.08 0.03 
20:3n-6 1.13 0.03 0.04 0.03 
20:4n-6 0.10 0.01 0.01 0.01 
20:5-n-3 0.62 0.02 0.01 0.01 
22:1n-9 0.66 0.04 0.08 0.03 
22:5n-3 0.11 0.03 0.12 0.03 
22:6n-3 0.05 0.04 0.03 0.03 
24:0 0.84 0.07 0.06 0.12 
24:1n-9 0.59 0.12 0.01 0.03 
c9-t11-18:2 0.87 16.82 0.03 0.05 
t10-c12-18:2  1.70 16.77 0.02 0.02 
c9-t11-c15-18:3 + c9-t13-c15-18:3 30.33 0.25 0.16 0.46 
Total conjugated 32.61 33.50 0.24 0.53 
SFA 10.24 9.63 9.92 9.95 
MUFA 23.86 21.92 23.90 23.34 
PUFA 65.87 68.45 66.23 66.81 
n-3:n-6 ratio 2.06 0.25 2.50 0.25 
SFA = total saturated fatty acids; MUFA = total monounsaturated fatty acid; PUFA = total 
polyunsaturated fatty acids; n-3:n-6 ratio = n-3 PUFA to n-6 PUFA ratio 
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Table 3: Basal plasma concentrations of glucose, insulin and C-peptide during OGTT or IVGTT according to the dietary 399 
treatments 400 
 Diet 
Index CLNA CLA W3 W6 SEM P-value 
OGTT       
Glucose 
(mmol/l) 
5.6 5.4 5.5 5.8 0.2 0.74 
Insulin 
(pmol/l) 
58.8 50.3 63.9 62.6 5.9 0.03 
C-peptide 
(pmol/l) 
53.0 64.4 68.3 49.9 7.9 0.27 
HOMA2-%S
a
 94.6 106.6 87.0 89.8 9.0 0.05* 
HOMA2-%B
a
 82.0 79.1 89.3 80.7 6.7 0.57 
IVGTT       
Glucose 
(mmol/l) 
5.8 5.3 5.3 5.6 0.3 0.26 
Insulin 
(pmol/l) 
57.3 64.3 55.2 58.9 6.9 0.62 
C-peptide 
(pmol/l) 
43.9 58.8 57.3 66.9 9.0 0.31 
HOMA2-%S
a
 88.5 102.3 98.8 92.7 12.5 0.76 
HOMA2-%B
a
 82.8 96.6 88.2 81.5 7.4 0.14 
W3 = omega-3 fatty acids diet; W6 = omega-6 fatty acids diet; CLNA = conjugated alpha-
linolenic acids diet; CLA = linoleic acids diet; OGTT=oral glucose tolerance test; IVGTT 
= intravenous glucose tolerance test.  
a
Calculated insulin sensitivity (HOMA2-%S) and β-cell function (HOMA2-%B) based on 
homeostatic model assessment [24]. 
*Specific contrasts p-values for CLNA vs. CLA, CLNA vs. W3 and CLNA vs. W6 were 
0.22, 0.53 and 0.81, respectively.   
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Table 4: Plasma glucose, insulin and C-peptide responses in OGTT and IVGTT 402 
 Diet 
Index CLNA CLA W3 W6 SEM P-value 
OGTT       
Glucose 
(mmol × min/l)
a
 
23.3 22.6 22.2 22.9 0.6 0.56 
Insuline 
(nmol × min/l)
a
 
478.3 441.1 453.0 426.4 36.4 0.70 
C-peptide 
(nmol × min/l)
a
 
618.5 550.5 573.8 563.8 52.6 0.68 
ISI (0, 210 min)
b
 7.7 8.7 7.7 7.9 0.6 0.21 
IVGTT       
Glucose 
(mmol × min/l)
a
 
28.5 27.6 28.2 27.5 0.9 0.81 
Insuline 
(nmol × min/l)
a
 
517.5 565.9 530.9 484.6 36.8 0.42 
C-peptide 
(nmol × min/l)
a
 
706.1 791.8 744.3 697.8 54.58 0.55 
SI (120, 210 min)
c
 5.0 4.5 4.7 5.4 0.68 0.51 
W3 = omega-3 fatty acids diet; W6 = omega-6 fatty acids diet; CLNA = conjugated alpha-linolenic acids 
diet; CLA = linoleic acids diet; OGTT = oral glucose tolerance test; IVGTT = intravenous glucose 
tolerance test;  
a
Values are AUC from 0 to 210 min during OGTT or IVGTT. 
b
Insulin sensitivity index (ISI) [26] calculated as follow: ISI= (Glubasal × Insbasal × Glumean × Insmean)
0.5
. 
c
Minimal model-derived insulin sensitivity index (SI) based on MINMOD Millennium [28]. 
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